Business Context and Reporting Period
Company: DexCom, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 4, 2025
Event: Receipt of a warning letter from the U.S. Food and Drug Administration (FDA) regarding manufacturing and quality management system deficiencies at facilities in San Diego, California, and Mesa, Arizona.
Key Financial Metrics
This filing is a regulatory disclosure and does not contain specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document references fiscal year 2025 revenue guidance previously issued on February 13, 2025, but does not restate those numbers.
Material Changes and Operational Impact
- Regulatory Action: The FDA issued a warning letter citing deficiencies in the Company's response to prior Form 483 observations from inspections conducted in mid-2024.
- Operational Restrictions: The warning letter does not restrict the Company's ability to produce, market, manufacture, or distribute products, nor does it require a product recall or restrict new 510(k) clearance applications.
- Financial Impact: Management states it does not expect a material impact on manufacturing capacity or the previously issued fiscal year 2025 revenue guidance.
Guidance, Outlook, and Risks
- Management Response: The Company is preparing a written response to the warning letter and intends to undertake corrective actions. Regular updates are being provided to the FDA.
- Uncertainty: The Company provides no assurance that the FDA will be satisfied with its response or regarding the timeline for resolution.
- Risks: Until resolved, the FDA may take additional legal or regulatory action without further notice. Forward-looking statements regarding the resolution of these matters are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the specific details of the FDA warning letter and the cited non-conformities in manufacturing processes.
- Monitor the Company's written response to the FDA and the agency's subsequent acceptance or rejection of corrective actions.
- Review the fiscal year 2025 revenue guidance issued on February 13, 2025, to confirm current targets remain unchanged.
- Watch for any future announcements regarding potential product recalls, manufacturing restrictions, or additional regulatory enforcement actions.